Page last updated: 2024-12-10

malealdehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

malealdehyde: RN given refers to cpd without isomeric designation; fumaraldehyde refers to (E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5323604
CHEBI ID38126
MeSH IDM0065663

Synonyms (13)

Synonym
3675-13-6
2-butenedial, (z)-
nsc 250971
(z)-2-butenedial
(2z)-but-2-enedial
CHEBI:38126
malealdehyde
cis-2-butene-1,4-dial
(z)-but-2-enedial
ccris 8401
Q27117385
DTXSID40878720
cis-butenedial

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In view of the multifunctional electrophilic reactivity of BDA, adduct formation with protein and DNA may explain some of the toxic effects."( Tests for genotoxicity and mutagenicity of furan and its metabolite cis-2-butene-1,4-dial in L5178Y tk+/- mouse lymphoma cells.
Brink, A; Kellert, M; Lutz, WK; Richter, I; Schlatter, J, 2008
)
0.35

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic data of rHSA-L-Talpha1 and rHSA-Talpha1 administered in rats showed an improved pharmacokinetic profile with a conspicuous prolonged half life."( Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.
Chen, J; Chen, JH; Cheng, DS; Jiang, YT; Tang, L; Wang, M; Yan, LY; Yin, YW; Zhang, XG, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
"In the present experiment, we aimed to determine the feasibility and curative effects of emodin combined with danshensu on experimental severe acute pancreatitis (SAP) and the mutual benefit of this synergistic strategy by a prospective animal study."( Protective effects of emodin combined with danshensu on experimental severe acute pancreatitis.
Gao, Y; Jiang, H; Li, X; Sun, B; Wang, G; Xue, D; Zhu, H, 2010
)
0.36
" SAP rats in each group received no further intervention, emodin alone, danshensu (DSS) alone, and emodin combined with DSS (EDSS), respectively."( Protective effects of emodin combined with danshensu on experimental severe acute pancreatitis.
Gao, Y; Jiang, H; Li, X; Sun, B; Wang, G; Xue, D; Zhu, H, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Using a benzylhydroxylamine dioxime derivative of [2H4]-labeled cis-1,4-dioxo-2-butene as an internal standard, the dose-response for the formation of 5'-(2-phosphoryl-1,4-dioxobutane) was determined to be linear for gamma-radiation, with approximately 6 lesions per 10(6) nt per Gy, and nonlinear for Fe2+-EDTA."( 5'-(2-phosphoryl-1,4-dioxobutane) as a product of 5'-oxidation of deoxyribose in DNA: elimination as trans-1,4-dioxo-2-butene and approaches to analysis.
Bohnert, T; Chen, B; Dedon, PC; Zhou, X, 2004
)
0.32
" This study used controlled dosing with furan in Fischer 344 rats to measure serum and liver toxicokinetics and the possible formation of BDA-nucleoside adducts in vivo."( Evaluation of serum and liver toxicokinetics for furan and liver DNA adduct formation in male Fischer 344 rats.
Beland, FA; Churchwell, MI; Doerge, DR; Gamboa da Costa, G; Scheri, RC; Von Tungeln, LS, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
but-2-enedial
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (68)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (7.35)18.7374
1990's2 (2.94)18.2507
2000's17 (25.00)29.6817
2010's36 (52.94)24.3611
2020's8 (11.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other71 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]